# US 2012/0251629 A1 · Methods of treatment and screening assays for hif-1alpha regulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251629 A1
- Document ID: US20120251629A1
- Status: Published application
- Kind: A1
- Application number: 13/501,066
- Filed: 2010-10-08
- Published: 2012-10-04
- Earliest claimed: 2009-10-09
- Assignees: University of Rochester
- Inventors: Marc Halterman
- Web page: https://patentgrep.com/patent/US20120251629A1

## CPC

- A61K 38/1703: {from vertebrates}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method of treating a patient for a condition where blood flow to a tissue or organ is interrupted. This method involves administering to a patient with a hypoxic condition where blood flow to a tissue or organ is interrupted, or at risk thereof, a compound that reduces the rate of HIF-1α inactivation in cells affected by the condition, thereby treating the patient for the condition. Also disclosed is a method of treating a tumor in a patient. In addition, the present invention relates to methods of identifying compounds as candidate drugs for treatment of hypoxic conditions and for treating tumors in a subject.

## Claims

### Claim 1

A method of treating a patient for a condition where blood flow to a tissue or organ is interrupted, said method comprising:
administering to a patient with a hypoxic condition where blood flow to a tissue or organ is interrupted, or at risk thereof, a compound that reduces the rate of HIF-1α inactivation in cells affected by the condition, thereby treating the patient for the condition.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the compound alters cellular activity of MKP-1 in hypoxic cells.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the compound is an MKP-1 inhibitor.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the hypoxic condition is selected from the group consisting of stroke, global ischemia after cardiac arrest, focal thrombotic and embolic large vessel stroke, small vessel stroke, asphyxiation, status epilepticus, carbon monoxide poisoning, fetal ischemic injury in utero for high risk pregnancy, systemic hypotension in shock, cardioprotection after acute coronary syndromes, and cerebral or systemic hypoxia sustained during bypass procedures.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the patient is at risk for the hypoxic condition.

### Claim 6

A method of treating a tumor in a patient, said method comprising administering to the patient a compound capable of disrupting activity of HIF-1α in tumor cells.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the compound is further capable of inactivating the protective activity of HIF-1α through activation of a putative proteolytic site and subsequent cleavage of HIF-1α by endogenous proteases.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the compound upregulates the activity of MKP-1 in tumor cells.

### Claim 9 (depends on 6)

The method according to claim 6, wherein the compound alters HIF-1α specific modifications permitting site specific cleavage by cellular proteases.

### Claim 10

A method of identifying compounds as candidate drugs for treatment of hypoxic conditions, said method comprising:
providing a cell expressing HIF-1α, wherein HIF-1α is cleaved or undergoes site-directed cleavage or proteolysis in the cell;
contacting the cell with compounds to be evaluated; and
selecting compounds capable of reducing HIF-1α cleavage and/or proteolysis in the cell as candidate drugs for treatment of hypoxic conditions.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the cell further expresses MKP-1.

### Claim 12 (depends on 11)

The method according to claim 11, wherein compounds are further selected based on their ability to down-regulate MKP-1 activity/expression in the cell.

### Claim 13 (depends on 10)

The method according to claim 10, wherein the cell further expresses pro-apoptotic proteins.

### Claim 14 (depends on 13)

The method according to claim 13, wherein compounds are further selected based on their ability to down-regulate activity of the pro-apoptotic proteins.

### Claim 15 (depends on 13)

The method according to claim 13, wherein the pro-apoptotic proteins are selected from BNIP3 and NOXA.

### Claim 16 (depends on 10)

The method according to claim 10, wherein the cell further expresses a protease known to cleave HIF-1α.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the compounds are further selected based on their ability to inhibit HIF-1α cleavage activity of the protease.

### Claim 18

A method of identifying compounds as candidate drugs for treating tumors in a subject, said method comprising:
providing a cell expressing active HIF-1α comprising a cleavage site;
contacting the cell with a compound to be evaluated; and
selecting a compound that either hyper-stimulates or inactivates HIF-1α as a candidate drug for treating tumors in a subject.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the cell expressing active HIF-1α is subject to hypoxic conditions and the compound that inactivates HIF-1α is selected by detecting no increase or a decrease of active HIF-1α in said cell.

### Claim 20 (depends on 18)

The method according to claim 18, wherein the compound is selected based an ability to activate HIF-1α cleavage.

### Claim 21 (depends on 18)

The method according to claim 18, wherein HIF-1α cleavage is detected by detecting more than one HIF-1α fragment in the cell.

### Claim 22 (depends on 18)

The method according to claim 18, wherein HIF-1α cleavage produces two or more distinct fragments of HIF-1α.

### Claim 23 (depends on 18)

The method according to claim 18, wherein HIF-1α cleavage is activated by MKP-1.

### Claim 24 (depends on 18)

The method according to claim 18, wherein the cell further expresses MKP-1.

### Claim 25 (depends on 24)

The method according to claim 24, wherein compounds are further selected based on their ability to upregulate MKP-1 activity/expression in the cell.
